| Stereochemistry | ABSOLUTE |
| Molecular Formula | C8H18N4O2 |
| Molecular Weight | 202.2541 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)C(=N)NCCC[C@H](N)C(O)=O
InChI
InChIKey=YDGMGEXADBMOMJ-LURJTMIESA-N
InChI=1S/C8H18N4O2/c1-12(2)8(10)11-5-3-4-6(9)7(13)14/h6H,3-5,9H2,1-2H3,(H2,10,11)(H,13,14)/t6-/m0/s1
| Molecular Formula | C8H18N4O2 |
| Molecular Weight | 202.2541 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
N, N – Dimethylarginine, more known as asymmetric dimethylarginine (ADMA), a naturally occurring chemical found in blood plasma. It is formed by methylation of arginine residues in proteins and released after proteolysis. ADMA is an endogenous inhibitor of all isoforms of nitric oxide synthase, the enzyme that synthesizes nitric oxide from arginine. Elevated plasma concentrations of ADMA are associated with hypertension and other risk factors for cardiovascular disease. It is known, that chronic kidney disease (CDK) is associated with increased risk of renal and cardiovascular events and it has been claimed that asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA), are contributing factors. Nevertheless, the recent comprehensive analysis of methylarginines in a cohort of patients with non-dialysis CKD have revealed, the potential pathophysiological role of SDMA in CKD progression and atherosclerotic cardiovascular disease among non-dialysis CKD patients. Thus SDMA predicts CKD progression and future atherosclerotic cardiovascular events more consistently than other methylarginines. In addition, was also shown, that the maternal plasma ADMA concentration is an important indicator of fetal growth restriction in women with impaired placental perfusion independent of NO.
CNS Activity
Approval Year
PubMed
Sample Use Guides
Asymmetric dimethylarginine (N,N-DIMETHYLARGININE; ADMA) induces the mitochondrial translocation of endothelial nitric oxide synthase (eNOS) through the nitration-mediated activation of Akt1. The study was performed to elucidate the potential effect of ADMA on Akt1 phosphorylation and the mechanisms that are involved. Western blot analysis demonstrated that, although ADMA (10 μM, 2 h) does not change total Akt1 levels. Akt1 phosphorylation at T308 and S473 were significantly increased. It was also found that ADMA treatment significantly increased Akt1 translocation from cytosol to the plasma membrane, suggesting that upon ADMA stimulation, Akt1 was activated, at least in part, through recruitment to that plasma membrane.
